Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
R-5780 + pd-1 inhibitor
- Development stage
- Unknown
- Lead developer
- Rise Therapeutics
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral (r-5780), Intravenous (PD-1 Inhibitor, E.g. Pembrolizumab, Nivolumab)
01
Overview
R-5780 + pd-1 inhibitor is an investigational combination therapy consisting of R-5780, an orally delivered synthetic biology-based probiotic intended to modulate gut-regulated immune pathways to enhance antitumor T cell responses, administered alongside a PD-1 checkpoint inhibitor, which unleashes T cell activity by blocking the PD-1 pathway on immune cells. The combination is designed for patients with solid tumors, particularly those refractory to immune checkpoint inhibitors, aiming to augment responsiveness and overcome resistance to PD-1-based immunotherapies. R-5780 is developed by Rise Therapeutics and represents a novel approach leveraging the gut-immune axis in conjunction with established checkpoint inhibition for improved cancer immunotherapy efficacy[1][3][4][6][7].
- Other names
- R-5780R5780R 5780R-5780-01R5780-01R 5780-01R-5780 + pd-1 inhibitorR-5780 + PD-1 checkpoint inhibitor
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on R-5780 + pd-1 inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on R-5780 + pd-1 inhibitor.